195 related articles for article (PubMed ID: 29330147)
1. Genetic Ablation of
Zhang J; Xu E; Ren C; Yang HJ; Zhang Y; Sun W; Kong X; Zhang W; Chen M; Huang E; Chen X
Cancer Res; 2018 Mar; 78(6):1511-1521. PubMed ID: 29330147
[TBL] [Abstract][Full Text] [Related]
2. PTEN expression is upregulated by a RNA-binding protein RBM38 via enhancing its mRNA stability in breast cancer.
Zhou XJ; Wu J; Shi L; Li XX; Zhu L; Sun X; Qian JY; Wang Y; Wei JF; Ding Q
J Exp Clin Cancer Res; 2017 Oct; 36(1):149. PubMed ID: 29052531
[TBL] [Abstract][Full Text] [Related]
3. RNA-binding protein RBM38 inhibits colorectal cancer progression by partly and competitively binding to PTEN 3'UTR with miR-92a-3p.
Guan B; Li G; Wan B; Guo X; Huang D; Ma J; Gong P; Guo J; Bu Y
Environ Toxicol; 2021 Dec; 36(12):2436-2447. PubMed ID: 34453780
[TBL] [Abstract][Full Text] [Related]
4. PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.
Zhang M; Xu E; Zhang J; Chen X
Oncogene; 2015 Nov; 34(48):5900-11. PubMed ID: 25823026
[TBL] [Abstract][Full Text] [Related]
5. Fine-tuning p53 activity by modulating the interaction between eukaryotic translation initiation factor eIF4E and RNA-binding protein RBM38.
Sun W; Laubach K; Lucchessi C; Zhang Y; Chen M; Zhang J; Chen X
Genes Dev; 2021 Apr; 35(7-8):542-555. PubMed ID: 33664057
[TBL] [Abstract][Full Text] [Related]
6. Mice deficient in Rbm38, a target of the p53 family, are susceptible to accelerated aging and spontaneous tumors.
Zhang J; Xu E; Ren C; Yan W; Zhang M; Chen M; Cardiff RD; Imai DM; Wisner E; Chen X
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18637-42. PubMed ID: 25512531
[TBL] [Abstract][Full Text] [Related]
7. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the Rbm38-eIF4E Complex with a Synthetic Peptide Pep8 Increases p53 Expression.
Lucchesi CA; Zhang J; Ma B; Chen M; Chen X
Cancer Res; 2019 Feb; 79(4):807-818. PubMed ID: 30591552
[TBL] [Abstract][Full Text] [Related]
9. A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy.
Huang X; Zhang Y; Tang Y; Butler N; Kim J; Guessous F; Schiff D; Mandell J; Abounader R
Neoplasia; 2013 Aug; 15(8):952-65. PubMed ID: 23908595
[TBL] [Abstract][Full Text] [Related]
10. RBM38 in cancer: role and mechanism.
Zou C; Wan Y; He L; Zheng JH; Mei Y; Shi J; Zhang M; Dong Z; Zhang D
Cell Mol Life Sci; 2021 Jan; 78(1):117-128. PubMed ID: 32642788
[TBL] [Abstract][Full Text] [Related]
11. Serine 195 phosphorylation in the RNA-binding protein Rbm38 increases p63 expression by modulating Rbm38's interaction with the Ago2-miR203 complex.
Zhang Y; Feng X; Sun W; Zhang J; Chen X
J Biol Chem; 2019 Feb; 294(7):2449-2459. PubMed ID: 30567739
[TBL] [Abstract][Full Text] [Related]
12. Glycogen synthase kinase 3 promotes p53 mRNA translation via phosphorylation of RNPC1.
Zhang M; Zhang J; Chen X; Cho SJ; Chen X
Genes Dev; 2013 Oct; 27(20):2246-58. PubMed ID: 24142875
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity.
Léveillé N; Elkon R; Davalos V; Manoharan V; Hollingworth D; Oude Vrielink J; le Sage C; Melo CA; Horlings HM; Wesseling J; Ule J; Esteller M; Ramos A; Agami R
Nat Commun; 2011 Oct; 2():513. PubMed ID: 22027593
[TBL] [Abstract][Full Text] [Related]
14. miR129-1 regulates protein phosphatase 1D protein expression under hypoxic conditions in non-small cell lung cancer cells harboring a TP53 mutation.
Yin HL; Xu HW; Lin QY
Oncol Lett; 2020 Sep; 20(3):2239-2247. PubMed ID: 32782541
[TBL] [Abstract][Full Text] [Related]
15. The role of c-Myc-RBM38 loop in the growth suppression in breast cancer.
Li XX; Shi L; Zhou XJ; Wu J; Xia TS; Zhou WB; Sun X; Zhu L; Wei JF; Ding Q
J Exp Clin Cancer Res; 2017 Apr; 36(1):49. PubMed ID: 28399911
[TBL] [Abstract][Full Text] [Related]
16. Suppression of T-cell lymphomagenesis in mice requires PTEN phosphatase activity.
Newton RH; Lu Y; Papa A; Whitcher GH; Kang YJ; Yan C; Pandolfi PP; Turka LA
Blood; 2015 Jan; 125(5):852-5. PubMed ID: 25477498
[TBL] [Abstract][Full Text] [Related]
17. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Choi HJ; Chung TW; Kang SK; Lee YC; Ko JH; Kim JG; Kim CH
Glycobiology; 2006 Jul; 16(7):573-83. PubMed ID: 16574813
[TBL] [Abstract][Full Text] [Related]
18. Post-transcriptional modulation of protein phosphatase PPP2CA and tumor suppressor PTEN by endogenous siRNA cleaved from hairpin within PTEN mRNA 3'UTR in human liver cells.
Gao YE; Wang Y; Chen FQ; Feng JY; Yang G; Feng GX; Yang Z; Ye LH; Zhang XD
Acta Pharmacol Sin; 2016 Jul; 37(7):898-907. PubMed ID: 27133296
[TBL] [Abstract][Full Text] [Related]
19. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.
Li Y; Guessous F; Kwon S; Kumar M; Ibidapo O; Fuller L; Johnson E; Lal B; Hussaini I; Bao Y; Laterra J; Schiff D; Abounader R
Cancer Res; 2008 Mar; 68(6):1723-31. PubMed ID: 18339852
[TBL] [Abstract][Full Text] [Related]
20. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.
Zhao K; Zhou Y; Qiao C; Ni T; Li Z; Wang X; Guo Q; Lu N; Wei L
J Hematol Oncol; 2015 Apr; 8():41. PubMed ID: 25902914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
